Literature DB >> 30478873

Characterization of children and adolescents with psychosis risk syndrome: The Children and Adolescents Psychosis Risk Syndrome (CAPRIS) study.

Montserrat Dolz1,2, Jordina Tor1,2, Elena De la Serna3,4, Marta Pardo1,2, Daniel Muñoz-Samons1,2, Marta Rodríguez-Pascual1, Olga Puig3, Gisela Sugranyes3,4, Judith Usall5, Vanessa Sánchez-Gistau3,6, Inmaculada Baeza3,4.   

Abstract

AIM: Despite the interest in psychosis risk syndrome (PRS) in children and adolescents, information on the syndrome in this population is scarce.
METHODS: Prospective naturalistic multi-site study in which 10- to 17-year-old help-seeking subjects who met PRS criteria (positive or negative attenuated symptoms; brief limited intermittent psychotic symptoms; genetic risk or schizotypal personality disorder plus impairment in functioning) were included, along with 45 age and sex-matched healthy controls (HC). All subjects were clinically and functionally assessed.
RESULTS: Ninety-one PRS subjects (PRSS) with a mean age of 15.5 ± 1.4 met inclusion criteria (IC). Compared with HC, PRSS presented worse global and academic functioning in the previous year, had experienced more psychiatric and psychological problems, and presented gestational ages outside the normal range. More than 80% of PRSS met ≥2 IC, with 65.9% having one Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis, and 61.7% of those having ≥2 diagnoses. Some 49.5% of PRSS had a first- or second-degree family history (FH) of psychosis. Patients with first- and second-degree FH do not differ in their clinical expression.
CONCLUSIONS: Children and adolescents with PRS are a patient group with a pattern of neurodevelopmental impairment and clinical complexity similar to patients with schizophrenia spectrum disorders, highlighting the importance of assessing these variables in child and adolescent samples. PRSS with first- and second-degree relatives with FH do not present differences in their clinical presentation, suggesting that including these two groups of patients in the genetic risk criteria would enrich knowledge of these criteria.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  child and adolescent; clinical high risk for psychosis; psychosis; psychosis risk syndrome

Year:  2018        PMID: 30478873     DOI: 10.1111/eip.12728

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  5 in total

Review 1.  Hand Washing: When Ritual Behavior Protects! Obsessive-Compulsive Symptoms in Young People during the COVID-19 Pandemic: A Narrative Review.

Authors:  Francesco Demaria; Maria Pontillo; Cristina Di Vincenzo; Michelangelo Di Luzio; Stefano Vicari
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

2.  Prognostic Accuracy of DSM-5 Attenuated Psychosis Syndrome in Adolescents: Prospective Real-World 5-Year Cohort Study.

Authors:  Martina Maria Mensi; Silvia Molteni; Melanie Iorio; Eleonora Filosi; Elena Ballante; Umberto Balottin; Paolo Fusar-Poli; Renato Borgatti
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306

3.  Major depressive disorder and attenuated negative symptoms in a child and adolescent sample with psychosis risk syndrome: the CAPRIS study.

Authors:  Marta Rodríguez-Pascual; Xavier Álvarez-Subiela; Jordina Tor; Marta Pardo; Elena de la Serna; Gisela Sugranyes; Olga Puig; Inmaculada Baeza; Montserrat Dolz
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-04-24       Impact factor: 5.349

4.  Auditory Mismatch Negativity in Youth Affected by Autism Spectrum Disorder With and Without Attenuated Psychosis Syndrome.

Authors:  Giorgio Di Lorenzo; Assia Riccioni; Michele Ribolsi; Martina Siracusano; Paolo Curatolo; Luigi Mazzone
Journal:  Front Psychiatry       Date:  2020-11-24       Impact factor: 4.157

5.  Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.

Authors:  Felice Iasevoli; Eugenio Razzino; Benedetta Altavilla; Camilla Avagliano; Annarita Barone; Mariateresa Ciccarelli; Luigi D'Ambrosio; Marta Matrone; Federica Milandri; Danilo Notar Francesco; Michele Fornaro; Andrea de Bartolomeis
Journal:  Early Interv Psychiatry       Date:  2021-05-16       Impact factor: 2.721

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.